Abstract 3863
Background
One third of early breast cancers (EBC) in women are diagnosed over 70 years (y) old. In this population, clinicians look not only at EBC characteristics but also antecedents and comorbidities to determine the best treatment.
Methods
ConSoRe is a new generation data analytics solution using natural language processing and perform advanced data mining. It was used for data extraction from electronic patient record of 2048 patients (pts) of more than 70 years, operated for EBC in Centre Leon Berard since 1997. Patient and tumor characteristics, treatment and survival were extracted.
Results
Mean age was 75.5 y (range 70-100 y). Main comorbidities described were coronary heart disease: 340 pts (16,6%) and diabetes: 321 pts (15,7%). Distribution of body mass index (BMI) was under 18.5: 56 pts (3,3%), 18.5-25: 677 pts (39,6%); 25-30: 620 (36,3%) and over 30: 356 (20,8%). Mean tumor size was 23,5 mm (range 6 to 150), SBR grading was distributed as well: grade 1: 317 (17%) ; grade 2: 1007 (55%) ; grade 3: 476 (26%) while estrogen receptor were positive (>10%) in 1553 pts (86%), progesteron receptor positive (>10%) in 1299 pts (71%) and HER2 positive in 101 pts (6,3%). Histological nodes staging was N0 in 1497 pts (72%); N1 in 414 pts (20%); N2 in 95 pts (5%); N3 in 52 pts (2%). 295 pts (14%) were treated by chemotherapy, 80 pts (3,9%) by trastuzumab, 1544 pts (75%) by radiotherapy and 1543 (75%) by hormonotherapy. Despite a limited mean follow-up of 5,1 y (range 0.3-20,7y), we observe 83 local relapse (4%), 144 metastatic relapse (7%) and 261 deaths (12.7%) with a mean overall survival (OS) of 4,6 y (10 days to 21,4 y). In the multivariate analysis, BMI under 19 and HER 2 positive were independent predictors of OS (HR: 0,85; p = 2.49e-09). Using Multiple Correspondence Analysis, percentage of explained variances is very low with less than 10%. These results show the limit of classical approach by descriptive data analysis, that is why, we propose new method by machine learning and operational research to determine the best adjuvant treatment.
Conclusions
This elderly population has a poor prognosis for which taking BMI into account is important when defining the therapeutic strategy. Classical approaches by data analysis reach their limits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Heudel Pierre.
Funding
Has not received any funding.
Disclosure
P. Heudel: Research grant / Funding (institution): AstraZeneca; Honoraria (institution): novartis; Honoraria (self): Pfizer. O. Tredan: Honoraria (self): Roche; Honoraria (self): Pfizer; Honoraria (self): novartis; Honoraria (self): AstraZeneca; Honoraria (self): lilly; Honoraria (self): BMS; Honoraria (self): MSD. All other authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract